Table 2 Subgroup analysis of pancreatic cancer foralcohol intake versus the lowest intake

Men

US

0.92 (0.69–1.21)

0.92 (0.77–1.11)

1.22 (0.95–1.56)

1.02 (0.83–1.25)

Europe

1.09 (0.88–1.36)

0.95 (0.62–1.46)

1.21 (0.84–1.76)

1.08 (0.90–1.30)

Other

0.64 (0.25–1.64)

1.06 (0.64–1.76)

0.89 (0.61–1.30)

0.91 (0.68–1.22)

Women

US

1.00 (0.87–1.14)

1.04 (0.79–1.35)

1.27 (0.98–1.65)

1.05 (0.94–1.16)

Europe

0.91 (0.50–1.64)

0.93 (0.75–1.15)

1.17 (0.70–1.97)

1.00 (0.82–1.23)

Other

0.83 (0.60–1.13)

0.88 (0.56–1.38)

1.23 (0.66–2.29)

0.89 (0.70–1.13)

Total cohort

US

0.97 (0.88–1.08)

1.00 (0.93–1.08)

1.22 (1.14–1.30)*

1.06 (0.98–1.14)

Europe

0.99 (0.85–1.15)

0.89 (0.80–1.00)

1.08 (0.91–1.27)

0.99 (0.90–1.10)

Other

0.81 (0.60–1.09)

0.95 (0.67–1.34)

0.97 (0.70–1.34)

0.90 (0.75–1.08)

Men

10 or more

1.01 (0.87–1.17)

0.89 (0.67–1.19)

1.07 (0.80–1.42)

1.00 (0.83–1.20)

<10

0.92 (0.56–1.51)

0.96 (0.79–1.17)

1.30 (1.11–1.52)*

1.06 (0.89–1.27)

Women

10 or more

0.96 (0.83–1.11)

0.93 (0.67–1.29)

1.40 (1.01–1.94)*

1.01 (0.89–1.14)

<10

0.98 (0.82–1.18)

1.01 (0.81–1.27)

1.04 (0.93–1.16)

0.99 (0.92–1.06)

Total cohort

10 or more

0.99 (0.89–1.09)

0.99 (0.91–1.08)

1.20 (1.07–1.34)*

1.02 (0.92–1.12)

<10

0.93 (0.81–1.06)

0.93 (0.85–1.03)

1.12 (0.99–1.26)

1.01 (0.93–1.10)

Men

Yes

0.98 (0.81–1.18)

0.94 (0.80–1.11)

1.19 (1.00–1.42)

1.04 (0.90–1.19)

No

1.02 (0.73–1.43)

0.82 (0.49–1.37)

0.99 (0.59–1.67)

0.96 (0.75–1.23)

Women

Yes

0.97 (0.87–1.09)

0.93 (0.83–1.04)

1.07 (0.96–1.19)

0.99 (0.93–1.06)

No

-

-

-

-

Total cohort

Yes

0.96 (0.89–1.05)

0.98 (0.92–1.04)

1.16 (1.06–1.26)*

1.02 (0.95–1.08)

No

1.02 (0.73–1.43)

0.82 (0.49–1.37)

0.99 (0.59–1.67)

0.96 (0.75–1.23)

Men

Yes

0.98 (0.81–1.18)

0.93 (0.79–1.10)

1.19 (0.98–1.46)

1.03 (0.88–1.20)

No

1.02 (0.73–1.43)

0.96 (0.66–1.40)

1.01 (0.70–1.47)

1.00 (0.81–1.23)

Women

Yes

0.94 (0.83–1.06)

0.90 (0.80–1.01)

1.07 (0.96–1.19)

0.97 (0.91–1.04)

No

1.18 (0.88–1.59)

1.42 (0.74–2.73)

1.20 (0.54–2.68)

1.25 (0.99–1.58)

Total cohort

Yes

0.96 (0.87–1.05)

0.98 (0.93–1.04)

1.17 (1.06–1.30)*

1.02 (0.95–1.09)

No

1.00 (0.83–1.21)

1.02 (0.80–1.31)

1.00 (0.77–1.28)

1.01 (0.87–1.17)

Men

Yes

0.93 (0.74–1.16)

0.92 (0.77–1.10)

1.15 (0.91–1.45)

0.99 (0.83–1.18)

No

1.08 (0.85–1.37)

1.00 (0.68–1.49)

1.11 (0.83–1.53)

1.06 (0.90–1.26)

Women

Yes

0.91 (0.80–1.04)

0.93 (0.74–1.17)

1.27 (0.99–1.64)

0.97 (0.87–1.07)

No

1.18 (0.94–1.49)

1.13 (0.78–1.65)

1.03 (0.92–1.16)

1.11 (0.91–1.34)

Total cohort

Yes

0.91 (0.83–1.01)

1.00 (0.94–1.06)

1.20 (1.12–1.28)*

0.99 (0.91–1.07)

No

1.11 (0.95–1.30)

1.02 (0.83–1.25)

1.05 (0.94–1.17)

1.06 (0.95–1.18)

Men

Yes

0.89 (0.72–1.10)

0.87 (0.73–1.04)

1.21 (0.96–1.52)

0.98 (0.81–1.18)

No

1.12 (0.92–1.36)

1.10 (0.82–1.48)

1.08 (0.84–1.40)

1.10 (0.94–1.29)

Women

Yes

0.97 (0.84–1.11)

0.94 (0.75–1.18)

1.36 (1.05–1.75)*

1.02 (0.92–1.13)

No

0.97 (0.74–1.27)

1.11 (0.77–1.60)

1.02 (0.91–1.14)

1.00 (0.87–1.15)

Total cohort

Yes

0.94 (0.84–1.04)

0.89 (0.78–1.03)

1.30 (1.14–1.47)*

1.00 (0.92–1.10)

No

1.00 (0.89–1.14)

0.99 (0.87–1.13)

1.09 (0.99–1.21)

1.03 (0.94–1.13)

Men

8 or 9

0.97 (0.82–1.14)

0.90 (0.72–1.13)

1.09 (0.87–1.37)

0.98 (0.83–1.16)

<8

1.20 (0.72–1.99)

0.96 (0.78–1.18)

1.22 (0.94–1.58)

1.17 (1.04–1.32)*

Women

8 or 9

0.96 (0.82–1.13)

0.99 (0.71–1.39)

1.48 (1.02–2.13)

1.01 (0.89–1.15)

<8

0.98 (0.82–1.18)

0.98 (0.80–1.20)

1.04 (0.93–1.16)

0.99 (0.92–1.06)

Total cohort

8 or 9

0.95 (0.87–1.05)

1.00 (0.94–1.06)

1.18 (1.06–1.31)*

0.99 (0.90–1.09)

<8

1.01 (0.85–1.19)

0.95 (0.84–1.08)

1.14 (0.99–1.30)

1.04 (0.96–1.13)